As the discontinuation rates were also high with the twice daily danuglipron at the phase 2 obesity trial (as discussed above), twice daily danuglirpon formulation will not advance into phase 3 studies, but an improved once-daily formulation with an aim to improve tolerability profile is currently under assessment [27]
Author: Natalie Ng|Updated: 5 June 2025 If youre taking GLP-1 medications or thinking about them as part of your weight loss plan, what you eat still plays a big role
Examining MT-II-induced dopamine release in the nucleus accumbens by in vivo microdialysis, studying how MC4R activation in the VTA alters dopamine neurone firing and downstream reward behaviour, and examining whether dopamine receptor antagonists attenuate the motivational components of MT-IIs pro-sexual and appetitive effects
Doctors treat folate deficiency by giving people folic acid
Saldanha O, et al
Recently, the NIH RECOVER-TLC initiative announced the inclusion of a major clinical trial investigating semaglutide for Long COVID, aiming to track how GLP-1 affects neuroinflammation and metabolic recovery